233 related articles for article (PubMed ID: 20981158)
1. The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.
Klyuchnikov E; Bacher U; Kröger N; Kazantsev I; Zabelina T; Ayuk F; Zander AR
Adv Hematol; 2011; 2011():974658. PubMed ID: 20981158
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Couriel D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE
Haematologica; 2008 Feb; 93(2):257-64. PubMed ID: 18223284
[TBL] [Abstract][Full Text] [Related]
4. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
5. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.
Porter DL; Stadtmauer EA; Lazarus HM
Bone Marrow Transplant; 2003 May; 31(9):739-46. PubMed ID: 12732878
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Bertz H; Illerhaus G; Veelken H; Finke J
Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience.
Nachbaur D; Oberaigner W; Fritsch E; Nussbaumer W; Gastl G
Eur J Haematol; 2001 Jan; 66(1):43-9. PubMed ID: 11168507
[TBL] [Abstract][Full Text] [Related]
8. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.
Hosing C; Saliba RM; McLaughlin P; Andersson B; Rodriguez MA; Fayad L; Cabanillas F; Champlin RE; Khouri IF
Ann Oncol; 2003 May; 14(5):737-44. PubMed ID: 12702528
[TBL] [Abstract][Full Text] [Related]
9. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
Claviez A; Sureda A; Schmitz N
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Canals C; Arranz R; Caballero D; Ribera JM; Brune M; Passweg J; Martino R; Valcárcel D; Besalduch J; Duarte R; León A; Pascual MJ; García-Noblejas A; López Corral L; Xicoy B; Sierra J; Schmitz N
Haematologica; 2012 Feb; 97(2):310-7. PubMed ID: 21993674
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation for Hodgkin's lymphoma.
Corradini P; Sarina B; Farina L
Br J Haematol; 2011 Feb; 152(3):261-72. PubMed ID: 21155760
[TBL] [Abstract][Full Text] [Related]
13. Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.
Karantanos T; Politikos I; Boussiotis VA
Blood Lymphat Cancer; 2017; 7():37-52. PubMed ID: 28701859
[TBL] [Abstract][Full Text] [Related]
14. The role of allogeneic stem cell transplantation in Hodgkin's lymphoma.
Sureda A; Domenech E; Schmitz N; Dreger P;
Curr Treat Options Oncol; 2014 Jun; 15(2):238-47. PubMed ID: 24752768
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience.
Verdonck LF
Leuk Lymphoma; 1999 Jun; 34(1-2):129-36. PubMed ID: 10350340
[TBL] [Abstract][Full Text] [Related]
16. Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis.
Lacerda MP; Arrais Rodrigues C; Pereira AD; Novis Y; Fonseca M; Silva RL; Macedo MCMA; Hamerschlak N; Esteves I; Schmidt Filho J; Nascimento MM; Rocha V
Biol Blood Marrow Transplant; 2017 Apr; 23(4):705-707. PubMed ID: 28108270
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
18. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
